This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Studies in Europe have linked a synthetic form of insulin to an increased risk of cancer, but doctors caution that the findings are preliminary and may not hold up under greater scrutiny. The drug, which has the brand name Lantus and is marketed by Sanofi-Aventis, provides a daily injection of artificial insulin.
We care about your feedback. Let us know how we can improve your CancerCompass experience.